Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Plc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Partnerships 12
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Licensing Agreements 19
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Equity Offering 24
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc – Key Competitors 27
Vernalis Plc – Key Employees 28
Vernalis Plc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Financial Announcements 31
Sep 12, 2017: Vernalis: Results Announcement for the year ended 30 June 2017 31
Jul 18, 2017: Vernalis: Year-End Trading Update and Notice of Full Year Results 33
Feb 21, 2017: Vernalis: Unaudited Interim Results for the six months ended 31 December 2016 34
Sep 29, 2016: Vernalis Announces Results Announcement for the 12 Months Ended 30 June 2016 36
Mar 17, 2016: Vernalis: Unaudited Interim Results Announcement for the six months ended 31 December 2015 38
Mar 17, 2016: Vernalis Announces Unaudited Interim Results Announcement for the Six Months Ended 31 December 2015 43
Corporate Communications 44
Apr 21, 2016: Vernalis Appoints Sandford Sommer as President & Chief Operating Officer, Vernalis Therapeutics 44
Government and Public Interest 45
Dec 01, 2016: Vernalis: AGM Statement 45
Product News 46
12/21/2016: FDA accepts CCP-08 NDA for full review 46
09/06/2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review 47
04/05/2017: Drug makes head-and-neck cancer more sensitive to radiotherapy 48
Product Approvals 49
Aug 07, 2017: FDA Issues a Complete Response Letter on CCP-08 NDA 49
Apr 21, 2017: FDA Issues a Complete Response Letter on CCP-07 NDA 50
Clinical Trials 51
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study 51
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study 52
Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
Vernalis Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vernalis Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 11
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis And Servier Extend Oncology Drug Discovery Agreement 15
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 16
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 17
Vernalis Expands Its Co-Development Agreement With Les Laboratoires Servier 18
Corvus Pharma Amends its Licensing Agreement with Vernalis 19
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 20
Vernalis Enters Into Licensing Agreement With Tris Pharma For Cough And Cold Products 21
Vernalis Enters into Licensing Agreement with RedoxTherapies 23
Vernalis to Raise USD58 Million in Private Placement of Shares 24
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 25
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 26
Vernalis Plc, Key Competitors 27
Vernalis Plc, Key Employees 28
Vernalis Plc, Subsidiaries 29